A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

NCT07459543 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Untreated Melanoma
Unresectable Melanoma
Metastatic Melanoma

Interventions

DRUG: Nivolumab + Relatlimab

Sponsor

Bristol-Myers Squibb